Prime Medicine shows firm upward price momentum over the past 1–6 months with the stock trading well above key moving averages, supported by multiple bullish technical signals and elevated volume. At the same time, fundamentals remain characterized by very small revenue, large operating losses, and deeply negative free cash flow, while valuation multiples on sales and book value appear high for a loss-making issuer. Short interest is elevated with a double‑digit percentage of shares sold short and a high days‑to‑cover figure, indicating notable positioning risk around sentiment shifts.